Herceptest assay

Manufactured by Agilent Technologies

The HercepTest assay is a qualitative immunohistochemical assay that detects the human epidermal growth factor receptor 2 (HER2) protein in formalin-fixed, paraffin-embedded breast cancer tissue samples. The assay is designed to aid in the assessment of patients for whom Herceptin (trastuzumab) treatment is being considered.

Automatically generated - may contain errors

Lab products found in correlation

Clone 636, by Agilent Technologies (1 mentions) Envision method, by Agilent Technologies (1 mentions)

2 protocols using herceptest assay

Immunohistochemical Profiling of Breast Tumors

Check if the same lab product or an alternative is used in the 5 most similar protocols

Prediluted antibodies for estrogen receptor (ER; clone EP1), progesterone receptor (PR; clone 636) and Ki67 (clone MIB-I) were obtained from Dako (Glostrup, Denmark). Sections were processed in a PT Module using Dako high pH buffer (Dako) for deparaffinization and antigen retrieval. Sections for the Ki-67 study were processed with Dako low pH buffer. All immunohistochemical stains were performed in an Autostainer Link using the EnVision method (Dako). HER2 overexpression was analyzed using the HercepTest assay (Dako). Tumors were classified as ER or PR positive when at least 1% of the tumor cells showed staining in the nuclei cells [29] (link). HER2 was considered overexpressed when a uniform intense (3 +) membrane staining was present in > 30% of invasive tumor cells [30] (link). The percentage of Ki67-stained nuclei was evaluated independently of the intensity and its positivity cutoff value was ≥ 20% [31] (link). Two pathologists independently evaluated all immunostainings, and discordant results were reviewed to reach an agreement.

Tibau A., López-Vilaró L., Pérez-Olabarria M., Vázquez T., Pons C., Gich I., Alonso C., Ojeda B., Ramón y Cajal T., Lerma E., Barnadas A, & Escuin D. (2014). Chromosome 17 Centromere Duplication and Responsiveness to Anthracycline-Based Neoadjuvant Chemotherapy in Breast Cancer. Neoplasia (New York, N.Y.), 16(10), 861-867.

+ Open protocol

+ Expand

Histological Evaluation of Xenograft HER2 Expression

Check if the same lab product or an alternative is used in the 5 most similar protocols

The xenografts and kidneys from each mouse in the therapy experiment were formalin-fixed and paraffin-embedded using standard procedures. For histologic evaluation, 4-mm sections were stained with hematoxylin and eosin. To evaluate HER2 expression after therapy, an immunohistochemical evaluation was performed using HercepTest Assay (Dako).

Westerlund K., Altai M., Mitran B., Konijnenberg M., Oroujeni M., Atterby C., de Jong M., Orlova A., Mattsson J., Micke P., Karlström A.E, & Tolmachev V. (2018). Radionuclide Therapy of HER2-Expressing Human Xenografts Using Affibody-Based Peptide Nucleic Acid-Mediated Pretargeting: In Vivo Proof of Principle. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 59(7).

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!